RT Journal Article
SR Electronic
T1 The human host response to monkeypox infection: a proteomic case series study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.27.22278027
DO 10.1101/2022.07.27.22278027
A1 Wang, Ziyue
A1 Tober-Lau, Pinkus
A1 Farztdinov, Vadim
A1 Lemke, Oliver
A1 Schwecke, Torsten
A1 Steinbrecher, Sarah
A1 Muenzner, Julia
A1 Kriedemann, Helene
A1 Sander, Leif Erik
A1 Hartl, Johannes
A1 Mülleder, Michael
A1 Ralser, Markus
A1 Kurth, Florian
YR 2022
UL http://medrxiv.org/content/early/2022/07/29/2022.07.27.22278027.abstract
AB Monkeypox (MPX) is caused by the homonymous orthopoxvirus (MPXV) known since the 1970s to occur at low frequency in West and Central Africa. Recently, the disease has been spreading quickly in Europe and the US. The rapid rise of MPX cases outside previously endemic areas and the different clinical presentation prompt for a better understanding of the disease, including the development of clinical tests for rapid diagnosis and monitoring. Here, using Zeno SWATH MS - a latest-generation proteomic technology - we studied the plasma proteome of a group of MPX patients with a similar infection history and clinical severity typical for the current outbreak. Moreover, we compared their proteomes to those of healthy volunteers and COVID-19 patients. We report that MPX is associated with a strong and characteristic plasma proteomic response and describe MPXV infection biomarkers among nutritional and acute phase response proteins. Moreover, we report a correlation between plasma protein markers and disease severity, approximated by the degree of skin manifestation. Contrasting the MPX host response with that of COVID-19, we find a range of similarities, but also important differences. For instance, Complement factor H-related protein 1 (CFHR1) is induced in COVID-19, but suppressed in MPX, reflecting the different role of the complement system in the two infectious diseases. However, the partial overlap between MPX and COVID-19 host response proteins allowed us to explore the repurposing of a clinically applicable COVID-19 biomarker panel assay, resulting in the successful classification of MPX patients. Hence, our results provide a first proteomic characterization of the MPX human host response based on a case series. The results obtained highlight that proteomics is a promising technology for the timely identification of disease biomarkers in studies with moderate cohorts, and we reveal a thus far untapped potential for accelerating the response to disease outbreaks through the repurposing of multiplex biomarker assays.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded in part by the Berlin Institute of Health (BIH), Wellcome Trust (IA 200829/Z/16/Z to M.R), by the Ministry of Education and Research (BMBF), as part of the National Research Node Mass spectrometry in Systems Medicine (MSCoresys), under grant agreement 031L0220 (to M.R). We further acknowledge funding by Deutsche Forschungsgemeinschaft (DFG) supporting Z.W.s PhD studies as part of the TRR 186.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Charité - Universitätsmedizin Berlin gave ethical approval for this work (EA2/139/22).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesInternal patient IDs were replaced at random within groups. Data matrix for discovery proteomics is available in (Supp. Table 1). Proteomic raw data will be made available on Pride (https://www.ebi.ac.uk/pride/) upon publication of the study.